Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2021 Mar 1.

Published in final edited form as: Am J Gastroenterol. 2020 Mar;115(3):415–434. doi: 10.14309/ajg.0000000000000544

Table 8.

Risk for Neoplasia at Second Surveillance Stratified by Findings at Baseline and First Surveillance

Baseline finding	First surveillance finding	HRA at second surveillance, %
Baseline finding	First surveillance finding	Morelli et al, 2013⁵⁵ (n = 965)	Park et al, 2015⁵⁶ (n = 2087)	van Heijningen, et al, 2013³⁰ (n = 1482)^a	Pinsky et al, 2009¹⁰⁹ (n = 1032)^a	Laiyemo et al, 2009¹¹⁰ (n = 1297)	Robertson et al, 2009¹¹¹ (n = 564)
LRA	No adenoma	6.6	6.0	1.0	3.9	2.8	4.9
	LRA	13.8	10.6	1.0	5.7	4.7	9.5
	HRA	18.0	16.4	0.0	15.6	6.9	20.0
HRA	No adenoma	9.6	6.7	4.0	5.9	4.8	12.3
	LRA	14.0	24.3	3.0	6.7	8.9	13.6
	HRA	22.0	38.2	4.0	19.3	30.6	18.2

HRA, high-risk adenoma; advanced adenoma or ≥3 adenomas; LRA, low-risk adenoma; 1–2 nonadvanced adenomas.

^a

Risk and outcome characterized based on nonadvanced and advanced adenoma.